Liu Hong-Li, Chen Jian
Gene and Immunotherapy Section, Institute of Immunology, Third Military Medical University, PLA, No. 30 Gaotanyan Street, Chongqing, People's Republic of China.
Cancer Biother Radiopharm. 2009 Feb;24(1):99-102. doi: 10.1089/cbr.2008.0559.
Oncolytic virus H101 is an adenovirus with an E1B-55KD gene deletion, which selectively replicates in tumor cells, rather than in normal cells, resulting in specific tumor cytolysis. Taking the selective killing of peritoneally planted tumor cells by the oncolytic virus H101 as the rationale for the ascites treatment, we report in this paper the intraperitoneal H101 in 9 patients with malignant ascites. The interval between the paracentesises increased from a mean of 12.4+/- 3.4 to 39.9 +/- 11.6 days (p < 0.001). The 30-day response was classified into complete response (CR) (no fluid recurrence), partial response (PR) (fluid recurrence <50%), and no response (NR) (fluid recurrence > or =50% or requiring paracentesis). Nine (9) patients had 3 CRs, 2 PRs, and 4 NRs. Intraperitoneal H101 was well tolerated, and no severe adverse effects were observed. Further, this report also highlights the potential of H101 in malignant ascites treatment.
溶瘤病毒H101是一种缺失E1B-55KD基因的腺病毒，它能在肿瘤细胞而非正常细胞中选择性复制，从而导致特异性肿瘤细胞溶解。基于溶瘤病毒H101对腹腔种植肿瘤细胞的选择性杀伤作用作为腹水治疗的理论依据，我们在本文中报告了9例恶性腹水患者腹腔注射H101的情况。穿刺间隔时间从平均12.4±3.4天延长至39.9±11.6天（p<0.001）。30天的反应分为完全缓解（CR）（无腹水复发）、部分缓解（PR）（腹水复发<50%）和无反应（NR）（腹水复发≥50%或需要穿刺）。9例患者中有3例CR、2例PR和4例NR。腹腔注射H101耐受性良好，未观察到严重不良反应。此外，本报告还强调了H101在恶性腹水治疗中的潜力。
